Zacks Investment Research upgraded shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) from a sell rating to a hold rating in a research note issued to investors on Thursday.

According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

Other analysts also recently issued reports about the company. SunTrust Banks, Inc. started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a buy rating and a $26.00 price target for the company. Stifel Nicolaus started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a buy rating and a $22.00 price target for the company. Jefferies Group LLC reiterated a buy rating and issued a $26.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, Wedbush started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued an outperform rating and a $25.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $22.60.

Verona Pharma PLC American Depositary Share (NASDAQ VRNA) opened at 12.4028 on Thursday. The company has a 50-day moving average price of $14.25 and a 200-day moving average price of $13.71. Verona Pharma PLC American Depositary Share has a 12-month low of $11.03 and a 12-month high of $17.50. The stock’s market capitalization is $79.63 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.09. On average, equities research analysts forecast that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/verona-pharma-plc-american-depositary-share-vrna-upgraded-to-hold-at-zacks-investment-research/1511994.html.

Institutional investors have recently bought and sold shares of the stock. FIL Ltd purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth $873,000. Tekla Capital Management LLC purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth $3,211,000. Finally, Vivo Capital LLC purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth $8,208,000. 10.46% of the stock is owned by institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.